BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions

–News Direct–

Best Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis on MeiraGTx Holdings plc a vertically integrated, clinical stage gene therapy company.

In a Recent Press Release, MeiraGTx Holdings plc (NASDAQ: MGTX) announced a $30 million strategic investment from Sanofi. This investment involves the purchase of 4.0 million ordinary shares of MeiraGTx at a price of $7.50 per share.

Best Growth Stock's full report breaks through the noise and offers an extensive comprehensive analysis of MeiraGTx potential near-term catalysts, this recent news event, growth strategy, and more.

Access this full Analysis:

(copy and paste to browser may be required)

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology that allows precise, dose responsive control of gene expression by oral small molecules with dynamic range that can exceed 5000-fold. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring, and developing technologies that give depth across both product candidates and indications. MeiraGTxs initial focus is on three distinct areas of unmet medical need: ocular diseases, including both inherited retinal diseases as well as large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx plans to expand its focus to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit

About Best Growth Stocks

Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions.

SOURCE: BestGrowthStocks.Com

Contact Details

Best Growth Stocks

Steve Macalbry

[email protected]

View source version on


comtex tracking